plerixafor has been researched along with Cancer of Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beaugie, C; Byrne, SN; Halliday, GM; Marsh-Wakefield, F; McDonald, D; Sarchio, SNE; Scolyer, RA | 1 |
| Aknin, ML; Bachelerie, F; Berrebi, D; Gaudin, F; Hémon, P; Meuris, F | 1 |
2 other study(ies) available for plerixafor and Cancer of Skin
| Article | Year |
|---|---|
Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer.
Topics: Animals; Benzylamines; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Movement; Chemokine CXCL12; Cyclams; Female; Fluoresceins; Gene Expression Regulation; Heterocyclic Compounds; Immune System; Lymph Nodes; Mast Cells; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms, Radiation-Induced; Receptors, CXCR4; Skin Neoplasms; Succinimides; Sunlight; Ultraviolet Rays | 2014 |
Symptomatic Improvement in Human Papillomavirus-Induced Epithelial Neoplasia by Specific Targeting of the CXCR4 Chemokine Receptor.
Topics: Animals; Apoptosis; Benzylamines; Cell Proliferation; Cells, Cultured; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Humans; Immunohistochemistry; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Papillomaviridae; Papillomavirus Infections; Random Allocation; Receptors, CXCR4; Skin Neoplasms | 2016 |